2023
An international research agenda for clozapine-resistant schizophrenia
Luykx J, Gonzalez-Diaz J, Guu T, van der Horst M, van Dellen E, Boks M, Guloksuz S, DeLisi L, Sommer I, Cummins R, Shiers D, Lee J, Every-Palmer S, Mhalla A, Chadly Z, Chan S, Cotes R, Takahashi S, Benros M, Wagner E, Correll C, Hasan A, Siskind D, Endres D, MacCabe J, Tiihonen J. An international research agenda for clozapine-resistant schizophrenia. The Lancet Psychiatry 2023, 10: 644-652. PMID: 37329895, DOI: 10.1016/s2215-0366(23)00109-8.Peer-Reviewed Original ResearchConceptsClozapine-resistant schizophreniaQuality of lifeTreatment optionsTreatment-resistant symptomsThird of patientsNew treatment optionsHealth care providersMiddle-income countriesFunctional outcomeInterventional studyUnmet needEpidemiological researchTranslational approachDiagnostic testsPatientsSchizophreniaHealth policyEarly detectionOptionsSymptomsDiagnosisTrials
2018
Resilience Against Traumatic Stress: Current Developments and Future Directions
Snijders C, Pries L, Sgammeglia N, Al Jowf G, Youssef N, de Nijs L, Guloksuz S, Rutten B. Resilience Against Traumatic Stress: Current Developments and Future Directions. Frontiers In Psychiatry 2018, 9: 676. PMID: 30631285, PMCID: PMC6315131, DOI: 10.3389/fpsyt.2018.00676.Peer-Reviewed Original ResearchEvaluation of the Association between Lithium Treatment and GSK3β Polymorphism in Bipolar Disorder Patients.
Altınbaş K, Yeşilbaş D, İnce B, Cansız A, Sılan F, Özdemir Ö, Gülöksüz S. Evaluation of the Association between Lithium Treatment and GSK3β Polymorphism in Bipolar Disorder Patients. Turkish Journal Of Psychiatry 2018, 29: 73-78. PMID: 30215834, DOI: 10.5080/u20582.Peer-Reviewed Original ResearchConceptsMean ageLithium treatmentTreatment responseGSK-3βBipolar disorder type IBipolar disorder patientsLack of evidenceClinical predictorsHospital recordsTreatment adherenceTreatment optionsDisease onsetFirst episodeReal-time PCRIndividualized treatmentPharmacogenomic findingsBlood samplesDisorder patientsSide effectsAG genotypeClinical practiceScale scoreBipolar disorderPatientsSample cohort
2014
The Immune System and Electroconvulsive Therapy for Depression
Guloksuz S, Rutten B, Arts B, van Os J, Kenis G. The Immune System and Electroconvulsive Therapy for Depression. Journal Of Ect 2014, 30: 132-137. PMID: 24755720, DOI: 10.1097/yct.0000000000000127.Peer-Reviewed Original ResearchConceptsEffects of ECTElectroconvulsive therapyImmune systemMechanism of actionImmune activationImmune functioningImpact of ECTTherapeutic actionTreatment-resistant depressionTransient immune activationPubMed/MEDLINEPossible roleImmunological changesCytokine concentrationsAdrenal axisTreatment optionsLarger sample sizeTreatment resultsPsychiatric conditionsSingle sessionRelevant articlesDefinitive conclusionsSearch termsSample sizeDepression
2011
P02-557 - Electroconvulsive therapy treated patients’ and their relatives’ attitudes toward electroconvulsive therapy
Saran O, Celik S, Guloksuz S, Cakmak D. P02-557 - Electroconvulsive therapy treated patients’ and their relatives’ attitudes toward electroconvulsive therapy. European Psychiatry 2011, 26: 1153. DOI: 10.1016/s0924-9338(11)72858-9.Peer-Reviewed Original ResearchMini-Mental State ExaminationMental State ExaminationElectroconvulsive therapyMemory problemsSubjective feelingsState ExaminationBakirkoy ResearchNegative viewsSide effectsBenefits of ECTClinical Global Impression ScaleMechanism of ECTOverall perceptionAttitudesPerceptionSubjective side effectsCommon side effectsAttitudes of patientsEffective treatment optionGlobal Impression ScaleImpression ScaleInpatient unitECT sessionsTreatment optionsPsychiatric illness
2010
The treatment of bipolar disorder during pregnancy and the postpartum period.
Gülöksüz S, Akdeniz F, Ince B, Oral E. The treatment of bipolar disorder during pregnancy and the postpartum period. Turkish Journal Of Psychiatry 2010, 21: 155-66. PMID: 20514566, DOI: 10.5080/u6131.Peer-Reviewed Original ResearchConceptsPostpartum periodBipolar disorderPsychotropic medicationsBD patientsOnset of BDRisk of relapseRisk-benefit decisionsNeonatal toxicityPregnant patientsAdverse eventsObstetrical outcomesFetal exposureSafety profileBreast milkPharmacological treatmentPrevent recurrenceTreatment optionsMedication effectsPsychotropic agentsReproductive yearsNeurobehavioral developmentRecurrence increasesPregnancyPatientsMedications